Mirvie

About Mirvie

Mirvie is a commercial-stage health technology company that provides predictive testing for pregnancy complications. Founded in 2018 by Maneesh Jain, Mads Melbye, and Stephen Quake, the company is headquartered in South San Francisco, California. The inspiration for the company came from co-founder Stephen Quake's personal experience with his daughter's premature birth. Quake, a Stanford University professor known for inventing non-invasive prenatal tests (NIPT) used by millions, led the initial research on using cell-free RNA (cfRNA) to predict preterm birth.

The company's core offering is the Mirvie RNA Platform, which uses a simple blood test to analyze tens of thousands of RNA messages from the mother, placenta, and baby. By applying machine learning to this transcriptomic data, the platform can detect the underlying biological drivers of various pregnancy complications months before symptoms appear. This enables a shift from reactive crisis management to proactive and personalized prenatal care. Mirvie's first commercial product, the Encompass™ test, is a blood test that predicts the risk of preeclampsia. Clinical studies have shown the platform can identify 75% of women who will develop preeclampsia and 76% of early preterm birth cases. Research also demonstrates its ability to predict severe fetal growth restriction.

Mirvie operates in the maternal health and diagnostics market, targeting obstetricians, maternal-fetal medicine specialists, and expectant parents. The company's business model centers on the commercialization of its diagnostic tests, conducted in its own CLIA-certified laboratory. To date, Mirvie has raised over $90 million in funding from investors including Khosla Ventures, Mayfield, Decheng Capital, General Catalyst, GV (formerly Google Ventures), and the Bill & Melinda Gates Foundation.